Try GOLD - Free
Reviving trends for healthcare economy
Bio Spectrum
|September 2020
While COVID-19 has wreaked havoc on the larger economy, the healthcare sector is no exception. With healthcare sector experiencing operating loss to the tune of Rs 14,000 to 24,000 crore for the first quarter with private sector reporting a 90 per cent drop in revenue, it has been a roller-coaster of a ride so far.
-
Dr Dharminder Nagar, Member- FICCI Health Services Committee and Managing Director, Paras Healthcare, Gurugram
How are we going to revive the sector once the virus goes away? The following measures or trends could revive the healthcare economy
It is expected that the health expenditure as a proportion of Gross domestic product (GDP) is likely to go up from 1.29 to 2.5 per cent by 2025. This would give an all-round stimulus to the sector with spill over effects across the entire value chain and the allied segments.
This story is from the September 2020 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
Breaking Ground in Clinical Trials: India's Innovation Imperative
For decades, India has been a global powerhouse in pharmaceutical manufacturing. Yet in clinical trials, the crucial bridge between laboratory discoveries and patient access, the country’s performance has lagged behind its industrial capabilities.
5 mins
November 2025
Bio Spectrum
MOFs for Next-Gen Therapies
Susumu Kitagawa, Richard Robson and Omar M Yaghi have been awarded the Nobel Prize in Chemistry 2025 for the development of a new type of molecular architecture called metal-organic frameworks (MOFs), opening new avenues for applications such as drug delivery, biomedical imaging and personalised medicine.
2 mins
November 2025
Bio Spectrum
We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM
Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram. The event brought together global innovators, researchers, investors, and industry leaders to explore opportunities, collaborations, and advancements across biotechnology, healthcare, digital health, and allied sectors. Organised by the Kerala Life Sciences Industries Park (KLIP) and the Kerala State Industrial Development Corporation (KSIDC), this conclave featured thought-provoking discussions, visionary keynote sessions, and cutting-edge technology showcases.
3 mins
November 2025
Bio Spectrum
The AI Job Loss Threat Conundrum
There are assumptions that Artificial Intelligence (AI) will take away pharma and healthcare jobs. But many are of the opinion that AI will help to transform jobs as well as create new ones in the long run. How much pharma and healthcare companies invest in AI and cope with the latest AI innovations will determine who can survive and who will perish. Let's find out.
5 mins
November 2025
Bio Spectrum
Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally
Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.
1 min
November 2025
Bio Spectrum
CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency
India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.
10 mins
November 2025
Bio Spectrum
When Spectra Speak: Letting AI Read the Fine Print of Biologics
Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.
5 mins
November 2025
Bio Spectrum
Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale
Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;
4 mins
November 2025
Bio Spectrum
Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad
Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.
1 min
November 2025
Bio Spectrum
Patient Consent - How is it different under medical ethics and data protection?
In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.
3 mins
November 2025
Translate
Change font size